Glaukos Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 1,094

Employees

  • Stock Symbol
  • GKOS

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $238.10
  • (As of Thursday Closing)

Glaukos General Information

Description

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Contact Information

Website
www.glaukos.com
Formerly Known As
Transdx
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • One Glaukos Way
  • Aliso Viejo, CA 92656
  • United States
+1 (949)
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Stock Exchange
NYS
Corporate Office
  • One Glaukos Way
  • Aliso Viejo, CA 92656
  • United States
+1 (949)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glaukos Stock Performance

As of 19-Nov-2026, Glaukos’s stock price is $238.10. Its current market cap is $14.1B with 59.2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$238.10 $233.08 $93.78 - $255.19 $14.1B 59.2M 1.18M -$2.94

Glaukos Financials Summary

As of 30-Sep-2026, Glaukos has a trailing 12-month revenue of $690M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 9,501,183 6,315,559 8,161,960 3,962,008
Revenue 690,332 507,442 383,481 314,711
EBITDA (133,130) (156,776) (106,744) (91,280)
Net Income (169,799) (187,691) (146,372) (134,661)
Total Assets 979,529 893,487 974,756 940,414
Total Debt 101,983 103,876 103,399 383,738
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Glaukos Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Glaukos‘s full profile, request access.

Request a free trial

Glaukos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Glaukos‘s full profile, request access.

Request a free trial

Glaukos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therap
Surgical Devices
Aliso Viejo, CA
1,094 As of 2025

Menlo Park, CA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glaukos Competitors (19)

One of Glaukos’s 19 competitors is Sight Sciences, a Formerly VC-backed company based in Menlo Park, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sight Sciences Formerly VC-backed Menlo Park, CA
Apollo Endosurgery Formerly VC-backed Austin, TX
Tivic Health Systems Formerly VC-backed Hayward, CA
Nova Eye Medical Corporation Kent Town, Australia
BVI Medical Private Equity-Backed Waltham, MA
You’re viewing 5 of 19 competitors. Get the full list »

Glaukos Patents

Glaukos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-252402-S Drug eluting ocular implant Active 26-Feb-2025
WO-2026177996-A1 Methods and systems for transferring viscous fluid to containers Pending 19-Feb-2025
US-20260174681-A1 Drug formulations and ocular implants having the same Pending 20-Dec-2024
WO-2026136907-A1 Drug formulations and ocular implants having the same Pending 20-Dec-2024
WO-2026050299-A1 Drug delivery implants as intraocular drug depots Pending 27-Aug-2024 A61F9/0017
To view Glaukos’s complete patent history, request access »

Glaukos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glaukos Investments & Acquisitions (5)

Glaukos’s most recent deal was a Merger/Acquisition with Mobius Therapeutics for . The deal was made on 16-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Mobius Therapeutics 16-May-2025 Merger/Acquisition Pharmaceuticals
Avedro 21-Nov-2019 Merger/Acquisition Pharmaceuticals
DOSE Medical 27-Jun-2019 Merger/Acquisition Drug Delivery
DOSE Medical (IOP sensor system assets and related liabilities) 12-Apr-2017 Corporate Asset Purchase Buildings and Property
DOSE Medical (iDose product line) 30-Jun-2015 Corporate Asset Purchase Buildings and Property
To view Glaukos’s complete investments and acquisitions history, request access »

Glaukos ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

22.43 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Glaukos’s complete esg history, request access »

Glaukos Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Mobius Therapeutics Saint Louis, MO 2006

Glaukos FAQs

  • When was Glaukos founded?

    Glaukos was founded in 1998.

  • Where is Glaukos headquartered?

    Glaukos is headquartered in Aliso Viejo, CA.

  • What is the size of Glaukos?

    Glaukos has 1,094 total employees.

  • What industry is Glaukos in?

    Glaukos’s primary industry is Surgical Devices.

  • Is Glaukos a private or public company?

    Glaukos is a Public company.

  • What is Glaukos’s stock symbol?

    The ticker symbol for Glaukos is GKOS.

  • What is the current stock price of Glaukos?

    As of 19-Nov-2026 the stock price of Glaukos is $238.10.

  • What is the current market cap of Glaukos?

    The current market capitalization of Glaukos is $14.1B.

  • What is Glaukos’s current revenue?

    The trailing twelve month revenue for Glaukos is $690M.

  • Who are Glaukos’s competitors?

    Sight Sciences, Apollo Endosurgery, Tivic Health Systems, Nova Eye Medical, and BVI Medical are some of the 19 competitors of Glaukos.

  • What is Glaukos’s annual earnings per share (EPS)?

    Glaukos’s EPS for 12 months was -$2.94.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process